Characterization of standard work tools for intrathecal baclofen therapy

Childs Nerv Syst. 2021 Oct;37(10):3073-3081. doi: 10.1007/s00381-021-05290-w. Epub 2021 Jul 14.

Abstract

Purpose: Intrathecal baclofen (ITB) has been an effective therapy since the 1980s, with widely reported revision, infection, and complication rates. Publications targeting surgical workflow have resulted in decreased infection and revision rates, but a standard workflow for the entire pathway has not been described. To present, define, and test standard work tools for patients receiving ITB to promote uniformity and standard of care in the field.

Methods: A multidisciplinary approach from the movement disorder program of a tertiary care center defined all steps comprising the ITB pathway, and then developed standard work tools to decrease variability with respect to preoperative workup, day of surgery protocol, post-operative care, and also evaluation and treatment with respect to pump infection or malfunction.

Results: Defined steps used at specific points of ITB pathway are presented with a single institution's outcome using the protocol from July 2017 to November 2020. A total of 60 procedures were performed. The overall complication rate was 14.5% at 6 months. Complications included an infection rate of 3.6% at 6 months, wound revision rate of 1.8% at 6 months, CSF leak rate of 1.7% at 6 months, and a 30-day readmission rate related to initial surgery of 6.7%.

Conclusions: Workflow efficiency and optimization for ITB patients can be used to obtain lower complication rates compared to historical cohorts in literature. A single-center, retrospective review highlights this.

Keywords: Complication; Dystonia; Infections; Intrathecal baclofen; Protocol; Quality improvement; Spasticity; Standard work.

MeSH terms

  • Baclofen* / therapeutic use
  • Humans
  • Infusion Pumps, Implantable
  • Injections, Spinal
  • Muscle Relaxants, Central* / therapeutic use
  • Muscle Spasticity / drug therapy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Muscle Relaxants, Central
  • Baclofen